Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$616.00K$616.00Kderived−83.1% vs Q4 2024 Net Income-$4.14M-$4.14MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$125,000−92.8% Operating Incomederived-$4,011,000N/M Operating Cash Flowderived-$1,590,000N/M Margins · derivedGross margin20.3%−27.5 pt vs Q4 2024
Operating margin-651.1%−606.9 pt vs Q4 2024
Net margin-672.4%−625.0 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 4, 2026 · 63 d after period end